For the newbies - worth reading - Dendrimers coming of Age, page-18

First 18 Last

Share
Profile

Follow
thrasher

4,850 Posts.

256

01/10/22

11:25

Post #: 63979287
Share

Originally posted by sarge17: ↑

Dr Behrenbruch got some pushback after his frank assessment of Starpharma. This was his reply:

As a number of (slightly cocky and goading) readers pointed out today, my prior post on Starpharma's utterly stupid pre-clinical announcement had a major flaw. In the interest of being comprehensive, I would like to make an additional follow-up comment, while completely acknowledging my own incompetence and stupidity.I was too busy telling you about the gaps in Starpharma's underwhelming mouse study. I was so busy reacting with ridicule that in climbing over itself to make a completely sensationalist but irrelevant ASX announcement, Starpharma didn't actually bother finishing the animals studies (still ongoing, apparently). I was so busy trying to recalibrate you on the lack of controls and the basic lack of meaningful information, that I forgot something super important.What is that you may ask?Well, the super-important information that I didn't see - but that several other people did - was the lack of efficacy in the Herceptin (naked antibody) and Kadcyla (ADC) comparative treatment arms. Duh. Below is a figure from a nice paper in Clinical Cancer Research from 2011 that shows the type of response we expect to see in a SKOV-3 model with Herceptin. I should note that the Herceptin (Trastuzumab) tumour response is very typical, per the references in this 2011 paper.So yes, the message you should take home is not only was Starphama's basic scientific integrity poor, and not only was the data incomplete, but the actual data itself is crap. I should also add that not only is it surprising that the company shows basically nil treatment effect in a xenograft model that is well known to respond well to Herceptin (and Kadycla), but also no dose is disclosed for the comparative treatment arms, nor any data on animal weight loss (to calibrate tumour volume changes). Both of which would be de rigeur …Sloppy, sloppy, sloppy.

Expand

Really your looking back to 2015 for negative stuff to post most posters here would have entered after that myself 2016, for heavens sake what has the Starpharma of 2015 got to do with the Starpharma of 2022, starting to get a bit concerned at where your going with this obsession sarge it's getting silly.

SPL Price at posting: 62.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 3 more messages in this thread...

First 18 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.00M

Open	High	Low	Value	Volume
9.8¢	10.5¢	9.6¢	$210.8K	2.098M

Buyers (Bids)

No.	Vol.	Price($)
1	30408	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.7¢	3523	2

View Market Depth

No.	Vol.	Price($)
1	30408	0.095
2	15638	0.094
3	83394	0.093
2	108435	0.091
2	41000	0.090

Price($)	Vol.	No.
0.097	3523	2
0.105	119848	4
0.110	114099	6
0.115	77331	6
0.120	89055	5

Last trade - 16.10pm 09/07/2024 (20 minute delay)

SPL (ASX) Chart

For the newbies - worth reading - Dendrimers coming of Age, page-18

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

For the newbies - worth reading - Dendrimers coming of Age, page-18

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News